Lannett gets FDA's blessing for generic Aggrenox

Press enter to search
Close search
Open Menu

Lannett gets FDA's blessing for generic Aggrenox

By Sandra Levy - 03/27/2019
Lannett has received approval from the Food and Drug Administration for aspirin and ER dipyridamole capsules, in a 25 mg/200 mg dosage strength.

The product is the generic of Boehringer Ingelheim’s Aggrenox capsules, 25 mg/200 mg.

The product had a market value of approximately $174.6 million for the 12 months ended January 2019, according to IQVIA, although actual generic market values are expected to be lower.

"The commercial opportunity for our aspirin and ER dipyridamole capsules product, which was developed internally, is meaningful," Lannett CEO Tim Crew said, adding, “The launch of this product is expected in the near term and is part of an ongoing and concerted effort, to add new products to our offering. Since January of last year, we have commenced marketing nearly 20 products and we expect to maintain that launch pace moving forward. We continue to make substantial investments in product development and expand in-licensing opportunities to replenish our pipeline, which is sizable relative to our portfolio, and add revenues and improve profitability."

Related Topics